Aegirbio AB has today signed a research & development agreement with MediaPharma Srl, an Italian biotech company focusing on novel drugs for the cure of cancer, and through this agreement Aegirbio intends to develop these drugs together with MediaPharma, in oncology and other areas. The unique characteristic of the cooperation is that Aegirbio’s Veritope technology […]
At the present, one of the major problems in cancer treatment lies in the lack of suitable assays to select patients more likely to respond to a given anticancer therapy.
MediaPharma intends to advance its proprietary products portfolio to initial clinical safety and efficacy endpoints, then form strategic partnerships with companies that have the necessary commercialization infrastructures to best capture value.
MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.
